Wolters Kluwer releases 2022 Annual Report
Wolters Kluwer releases2022 Annual Report
Annual Report and materials forAnnual General Meeting of Shareholders availableonline
Alphen aan den Rijn – March 8, 2023 – Wolters Kluwer, a global provider of professional information, software solutions, and services, today published its 2022 Annual Report. The 2022 Financial Statements, as included in the 2022 Annual Report, will be proposed for adoption at the Annual General Meeting of Shareholders (AGM) on May 10, 2023.
The 2022 Annual Report provides detailed insights into Wolters Kluwer’s financial and non-financial performance during 2022. The report is available on our company website at www.wolterskluwer.com/annual-report, where an XBRL version in the European Single Electronic Format (ESEF) is also available for download.
The AGM will be held on May 10, 2023. The agenda with explanatory notes and the convocation notice for the AGM is available at www.wolterskluwer.com/agm. The agenda includes a proposal to distribute a total dividend over the 2022 financial year of €1.81 per ordinary share. If approved, this will result in a final dividend of €1.18 per ordinary share. In addition, the agenda includes proposals to reappoint Mr. Chris Vogelzang as member of the Supervisory Board and to appoint KPMG Accountants N.V. as the external auditor of the company for financial years 2025 – 2028. The AGM will be held in a hybrid format, enabling shareholders to attend, ask questions, and vote virtually or in person.
About Wolters Kluwer
Wolters Kluwer (EURONEXT: WKL) is a global leader in professional information, software solutions, and services for the healthcare, tax and accounting, financial and corporate compliance, legal and regulatory, and corporate performance and ESG sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with specialized technology and services.
Wolters Kluwer reported 2022 annual revenues of €5.5 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 20,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.
Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt (ADR) program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).
For more information, visit www.wolterskluwer.com, follow us on LinkedIn, Twitter, Facebook, and YouTube.
May 3, 2023 First-Quarter 2023 Trading Update
May 10, 2023 Annual General Meeting of Shareholders
May 12, 2023 Ex-dividend date: 2022 final dividend
May 15, 2023 Record date: 2022 final dividend
June 6, 2023 Payment date: 2022 final dividend, ordinary shares
June 13, 2023 Payment date: 2022 final dividend, ADRs
August 2, 2023 Half-Year 2023 Results
August 29, 2023 Ex-dividend date: 2023 interim dividend
August 30, 2023 Record date: 2023 interim dividend
September 21, 2023 Payment date: 2023 interim dividend
September 28, 2023 Payment date: 2023 interim dividend, ADRs
November 1, 2023 Nine-Month 2023 Trading Update
February 21, 2024 Full-Year 2023 Results
March 6, 2024 Publication of 2023 Annual Report
|Gerbert van Genderen Stort||Meg Geldens|
|Corporate Communications||Investor Relations|
|t + 31 172 641 230||t + 31 172 641 407|
Forward-looking statements and other important legal information
This report contains forward-looking statements. These statements may be identified by words such as “expect”, “should”, “could”, “shall” and similar expressions. Wolters Kluwer cautions that such forward-looking statements are qualified by certain risks and uncertainties that could cause actual results and events to differ materially from what is contemplated by the forward-looking statements. Factors which could cause actual results to differ from these forward-looking statements may include, without limitation, general economic conditions; conditions in the markets in which Wolters Kluwer is engaged; behavior of customers, suppliers, and competitors; technological developments; the implementation and execution of new ICT systems or outsourcing; and legal, tax, and regulatory rules affecting Wolters Kluwer’s businesses, as well as risks related to mergers, acquisitions, and divestments. In addition, financial risks such as currency movements, interest rate fluctuations, liquidity, and credit risks could influence future results. The foregoing list of factors should not be construed as exhaustive. Wolters Kluwer disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Elements of this press release contain or may contain inside information about Wolters Kluwer within the meaning of Article 7(1) of the Market Abuse Regulation (596/2014/EU).
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
TRESU Investment Holding A/S – Registration for investor call28.3.2023 11:04:29 CEST | Press release
TRESU INVESTMENT HOLDING A/S ANNOUNCEMENT NO. 02.2023 28.03.2022 TRESU Investment Holding A/S is pleased to invite you to the financial results call, which is being held: Wednesday, 5 April 2022, at 11am CET. The Annual Report will be presented by Christian Jacob Flarup, CEO and Torben Børsting, CFO. After the presentation there will be an opportunity for Q+A. A recording of the results call will be made available for four hours on the TRESU IR website. To register for the investor call, please send an e-mail to Financial manager at TRESU A/S Finn Holm no later than 4 April 2023 9am CET - email@example.com Christian Jacob Flarup CEO, TRESU For further details, please contact: CEO, Christian Jacob Flarup, phone: +45 2027 7971 CFO, Torben Børsting, phone: +45 5130 2780 Attachment Quarterly reporting - Call - 2022 Q4
Alvotech Provides Update on Corporate Sustainability Framework28.3.2023 11:00:00 CEST | Press release
Alvotech (Nasdaq: ALVO) (the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced an update to the Company’s Corporate Sustainability framework, including the release of key environmental, social and governance (“ESG”) indicators for 2022. “As part of our commitment to improve the sustainability of healthcare by providing access to more affordable biologic medicines, we recognize that corporate sustainability is closely linked to our long-term success and the value we may bring to patients, healthcare providers and all of our stakeholders,” said Robert Wessman, Founder, Chairman and CEO of Alvotech. Data on key ESG indicators for 2020-2022 can be found on Alvotech’s dedicated web portal. Alvotech’s Board of Directors has established a Corporate Sustainability Committee (CSC) to oversee the Company’s strategy as it relates to ESG matters. Alvotech’s corporate headquarters, purpose-built manuf
Zealand Pharma Announces Positive Phase 1 Clinical Results with Amylin Analogue ZP839628.3.2023 10:54:21 CEST | Press release
Company announcement – No. 7 / 2023 Zealand Pharma Announces Positive Phase 1 Clinical Results with Amylin Analogue ZP8396 Dose-dependent body weight reductions of up to a mean of 4.2% from baseline (4.8% placebo corrected) following a single dose of ZP8396In development as a non-incretin peptide therapyfor the potential management of overweight and obesity Copenhagen, Denmark, March 28, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) (CVR-no. 20045078) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced Phase 1a results for ZP8396, the company’s amylin analogue. The first-in-human study was designed to assess safety, pharmacokinetic (PK) and pharmacodynamic effects of ZP8396 in healthy lean and overweight people. “We are excited by the potential of amylin as an alternative, non-incretin treatment for overweight and obesity, and are very encouraged that treatment with a single dose of ZP8396 led to meaningful dose
Indkaldelse til ordinær generalforsamling i SKAKO A/S28.3.2023 10:50:52 CEST | pressemeddelelse
Til NASDAQ OMX Copenhagen A/S GlobeNewswire Faaborg, den 28. marts 2023 Selskabsmeddelelse nr. 5/2023 Indkaldelse til ordinær generalforsamling i SKAKO A/S SKAKO A/S indkalder til ordinær generalforsamling i selskabet til afholdelse onsdag den 19. april 2023, kl. 15.00 på selskabets adresse. Indkaldelsen er sket jf. selskabets vedtægter § 7 og er tilgængelig på selskabets hjemmeside. Udbytte På baggrund af det stærke resultat i 2022 og kapitalstrukturen i SKAKO A/S pr. 31. december 2022 anbefaler bestyrelsen en udbytteudlodning på DKK 5 pr. aktie svarende til 61,0% af årets resultat og en samlet udbytteudlodning på DKK 15,4 mio. Med en aktiekurs på 62,6 kr. pr. 31. december 2022 svarer det til en udbytteprocent på 8,0%. Udbyttebetalingen vil være et behandlingspunkt på agendaen for den ordinære generalforsamling 19. april 2023. Ex-udbytte dato: 19. april 2023 Optagelsesdato: 20. april 2023 Udbetalingsdato: 24. april 2023 Med venlig hilsen SKAKO A/S Jens Wittrup Willumsen Bestyrelsesfor
Aalborg Boldspilklub A/S indkalder til ordinær generalforsamling28.3.2023 10:50:49 CEST | pressemeddelelse
NASDAQ Copenhagen A/S Børsmeddelelse nr. 2023/06 Aalborg, 28. marts 2023 Vedhæftet indkaldelse og dagsorden til ordinær generalforsamling i Aalborg Boldspilklub A/S onsdag 19. april 2023 kl. 16.00 på Aalborg Portland Park. Venlig hilsen Aalborg Boldspilklub A/S Thomas Bælum Administrerende direktør For yderligere oplysninger: Thomas Bælum 2251 7901 Vedhæftede filer Dagsorden 2023 - Inkl Bilag A og Bilag BAAB_ Brevstemme blanket_GF2023_v5